🇺🇸 FDA
Pipeline program

Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated)

090701

Phase 3 mab completed

Quick answer

Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) for Hemophilia A or B With Inhibitors is a Phase 3 program (mab) at Baxalta Innovations GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Baxalta Innovations GmbH
Indication
Hemophilia A or B With Inhibitors
Phase
Phase 3
Modality
mab
Status
completed

Clinical trials